Compare Novo Nordisk A/S (NVO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Consumer Staples Select Sector SPDR Fund trades at $84.01. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | XLP | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | — |
52-Week High | $71.70 | $90.00 |
52-Week Low | $35.29 | $75.61 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
XLP trades at $84.86, down 0.39% with a bullish technical signal from moving averages. The ETF shows strong analyst support with a 100% buy rating from 2 analysts and a 2.6% dividend yield. Recent news highlights XLP's defensive positioning amid market volatility, with consumer staples gaining favor as investors seek stability.
The outlook remains positive given XLP's defensive sector exposure and strong technical momentum. Key risks include sector concentration and macroeconomic pressures on consumer spending. With unanimous analyst bullishness and technical indicators supporting further upside, XLP presents a stable equity opportunity in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
